Skip to main
CRMD
CRMD logo

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix Inc. has significantly raised its full-year 2025 pro forma net revenue guidance to a range of $390–$410 million, reflecting robust adoption of its product, DefenCath, and anticipated contributions from the Melinta portfolio. The company projects a fourth-quarter net revenue between $115 million and $135 million, indicating a strong momentum heading into the year's end, supported by higher utilization among outpatient dialysis customers. Additionally, Cormedix reported better-than-expected performance in Q3 2025, with net revenue of $104.3 million, underscoring its positive commercial execution strategy and positioning for future growth.

Bears say

Cormedix Inc. faces potential financial challenges, particularly with expectations of a significant price drop for its product DefenCath upon the second phase of the Transitional Drug Add-on Payment Adjustment (TDAPA) in July 2026. While there is a projected market opportunity for the company's other product, Niyadas, estimated between $100 million and $200 million, the implications of TDAPA pricing uncertainties loom large over the company's revenue prospects. Additionally, the competitive landscape for catheter lock solutions, particularly against established generics like Heparin, raises concerns about DefenCath's ability to meet sales projections.

CorMedix (CRMD) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 6 analysts, CorMedix (CRMD) has a Buy consensus rating as of Dec 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.